All News

sick kid child temperature fever

IVIg in MIS-C

d Jack Cush, MD

Among children with multisystem inflammatory syndrome (MIS-C), treatment with IVIG and methylprednisolone vs IVIG alone was associated with a more favorable fever course. MIS-C is a rare but serious pediatric condition associated with COVID-19 where different body parts can become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs.

Read Article
Lknee.OA_.jpg

NSAIDs in Osteoarthritis: Study Suggests Need for New Look

d Jack Cush, MD

Knee osteoarthritis (OA) patients using nonsteroidal anti-inflammatory drugs (NSAIDs) showed greater loss of medial minimum joint space width than did others taking other drugs, registry data indicated.

Read Article
narcotics_0.jpg

Abrupt Cessation of Long-Term Opioid Prescribing Common

d MedPage Today

Medicare beneficiaries were increasingly likely to have long-term opioid therapy stopped in recent years and medication changes often were abrupt, not tapered, an observational study showed.

Read Article
RheumNow Podcast square

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

d Jack Cush, MD

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Hydroxychloroquine Fails to Prevent COVID-19

d Jack Cush, MD

There is a preponderance and mounting evidence that hydroxychloroquine is ineffective in COVID-19 infection; and now the NEJM reports a the results of a trial where HCQ given as post-COVID exposure therapy failed to prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons.

Read Article
FDA-Building_1.png

Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA

d Jack Cush, MD

The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz), noting that preliminary results from a long-term safety clinical trial show an increased risk of serious heart-related problems and cancer with tofacitinib (compared to adalimumab) when given to

Read Article
UK Biobank examined the association between comorbidities & uric acid (SUA). Comorbidities assoc w/ increasing SUA. For each 1 mg increase in SUA, there is a 1-3 fold incr risk of HTN, IHD, CCF, ^HL, CKD https://t.co/ZEPAPRq62k

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! Tofacitinib Safety Concerns - covering vagal nerve stimulation, IL-23 in PsA, Diet & RA, NSAIDs & COVID, Plaquenil side effects and more. Watch it here>> https://t.co/7RDZ0avZLC ListeniTunes>>https://t.co/FHJv01AAbC or SoundCloud>>https://t.co/yJWJNa6CRL

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - Chronic Monarthritis Treatment Considerations on Chronic Monarthritis https://t.co/7VmH1skHhb

Links:

Dr. John Cush RheumNow ( View Tweet)

Download available--30 FDA Approved Biologics in Rheumatology https://t.co/HSvllkDUz7

Links:

Dr. John Cush RheumNow ( View Tweet)

Abrupt Cessation of Long-Term Opioid Prescribing Common Medicare beneficiaries were increasingly likely to have long-term opioid therapy stopped in recent years and medication changes often were abrupt, not tapered, an observational study showed. https://t.co/bCnaJHECd0 https://t.co/ermkbK6LMN

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – Tofacitinib Safety Concerns Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow. https://t.co/7RDZ0avZLC https://t.co/iUJFuf8PNj

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - What Were You Thinking Pet Peeve Issues in Patient Care https://t.co/BpjXbsdWr5

Links:

Dr. John Cush RheumNow ( View Tweet)

HCQ Fails to Prevent COVID-19 Mounting evidence shows that HCQ is ineffective in COVID-19 infection; and now the NEJM reports that HCQ given as post-COVID exposure therapy failed to prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons. https://t.co/lt71GAtL3D https://t.co/VzmJgQlrrG

Links:

Dr. John Cush RheumNow ( View Tweet)
Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz) when given to at-risk rheumatoid arthritis patients. https://t.co/RJD8CMouHK https://t.co/bipwWlIhiB

Links:

Dr. John Cush RheumNow ( View Tweet)
PSOLAR study of 298 pregnancies in 220 women with mod-severe psoriasis. 82% resulted in live births and rates of spontaneous abortion and congenital anomalies same as US population. Biologic exposure pregnancy outcomes same as those not on biologics https://t.co/GKXyDGRILD

Links:

Dr. John Cush RheumNow ( View Tweet)

OpenSAFELY analysis shows that NSAIDs safe w/ COVID. Study 1: 1/2 million NSAID users vs ~2 mill non-users found no difference in COVID-19 death (HR 0.96); Study 2: 1.7 million RA/OA pts, 10% on NSAIDs had a lower risk of COVID-19 death (HR 0.78) https://t.co/1f3JBmaf2e

Links:

Dr. John Cush RheumNow ( View Tweet)

More on Vagal Nerve Stimulation in RA (https://t.co/OykGWP76qd) The device used was an earbud, designed to deli)ver electrical pulse sequences to target the cholinergic anti-inflammatory pathway. They called this neural input methodology, e-mmunotherapy https://t.co/iubW0sZgIs https://t.co/cKlzRXKkLT

Links:

Dr. John Cush RheumNow ( View Tweet)
Adverse Events with Anti-malarials during the COVID Pandemic Despite very preliminary mixed results, the endorsement of chloroquine and hydroxychloroquine use to treat COVID-19 led substantial use (and drug shortages) for these drugs. https://t.co/UQYo3a8ZKI

Links:

Dr. John Cush RheumNow ( View Tweet)

Health Canada Approves Subcutaneous Infliximab Biosimilar The infliximab biosimilar CT-P13, developed by Celltrion and marketed as Remsima has been approved by HealthCanad for subcutaneous (SC) use in all the indications for infliximab. https://t.co/7pS7y4sys9

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×